

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

JAN 28 2004

Sheet

1

of

APPLICATION NO.: 09/888,326

ATTY. DOCKET NO.: C1039.70052US00

FILING DATE: June 22, 2001

CONFIRMATION NO.: 7237

APPLICANT: Weiner et al.

GROUP ART UNIT: 1635


EXAMINER: Jon E. Angel

## U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	A40	2002/0091097	A1	Bratzler et al.	07-11-2002
	A41	2002/0164341	A1	Davis et al.	11-07-2002
	A42	2003/0050263	A1	Krieg et al.	03-13-2003
	A43	2003/0050268	A1	Krieg et al.	03-13-2003
	A44	2003/0091599	A1	Davis et al.	05-15-2003
	A45	2003/0055014	A1	Bratzler	03-20-2003
	A46	2003/0100527	A1	Krieg et al.	05-29-2003
	A47	2003/0104523	A1	Lipford et al.	06-05-2003
	A48	2003/0139364	A1	Krieg et al.	07-24-2003
	A49	2003/0148976	A1	Krieg et al.	08-07-2003
	A50	2003/0148316	A1	Lipford et al.	08-07-2003
	A51	2003/0166001	A1	Lipford	09-04-2003
	A52	2003/0181406	A1	Schetter et al.	09-25-2003
	A53	2003/0191079	A1	Krieg et al.	10-09-2003
	A54	2003/0232074	A1	Lipford et al.	12-18-2003

## FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
	B34	WO	02/069369	A2		09-06-2002	

EXAMINER  DATE CONSIDERED 11-24-04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_, filed \_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]

## GROUP ART UNIT: 1645

EXAMINER: unknown

Sheet 87 of 2

U.S. PATENT DOCUMENTS

Examiner's Initials#	U.S. Patent Document No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

FOREIGN PATENT DOCUMENTS **TECH CENTER 1600/2900**

Examiner's Initials#	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			

### OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials#	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
✓	C122	BOERNER P et al., Production of antigen-specific human monoclonal antibodies from in vitro-primed human splenocytes. <i>J Immunol.</i> 1991 Jul 1;147(1):86-95.	
✓	C123	CHAPEROT L et al., Functional expression of CD80 and CD86 allows immunogenicity of malignant B cells from non-Hodgkin's lymphomas. <i>Exp Hematol.</i> 1999 Mar;27(3):479-88.	
✓	C125	DAVIS TA et al., Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. <i>J Clin Oncol.</i> 1999 Jun;17(6):1851-7.	
✓	C124	DAVIS TA et al., Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. <i>Clin Cancer Res.</i> 1999 Mar;5(3):611-5.	
	C126	ELSASSER D et al., HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor. <i>Blood.</i> 1996 May 1;87(9):3803-12.	
	C127	FORAN JM et al., European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. <i>J Clin Oncol.</i> 2000 Jan;18(2):317-24.	
	C128	FUNAKOSHI S et al., Inhibition of human B-cell lymphoma growth by CD40 stimulation. <i>Blood.</i> 1994 May 15;83(10):2787-94.	
	C129	GINALDI L et al., Levels of expression of CD19 and CD20 in chronic B cell leukaemias. <i>J Clin Pathol.</i> 1998 May;51(5):364-9.	
	C130	GORDON J et al., Regulation of survival in normal and neoplastic B lymphocytes. <i>Leukemia.</i> 1993 Aug;7 Suppl 2:S5-9.	
	C131	GORDON J et al., Signals for survival and apoptosis in normal and neoplastic B lymphocytes. <i>Adv Exp Med Biol.</i> 1996;406:139-44.	
	C132	GRILLO-LOPEZ AJ et al, Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. <i>Semin Oncol.</i> 1999 Oct;26(5 Suppl 14):66-73.	
	C133	HIGAKI Y et al., Mechanisms involved in the inhibition of growth of a human B lymphoma cell line, B104, by anti-MHC class II antibodies. <i>Immunol Cell Biol.</i> 1994 Jun;72(3):205-14.	
	C134	JAKOBOVITS A et al., Germ-line transmission and expression of a human-derived yeast artificial chromosome. <i>Nature.</i> 1993 Mar 18;362(6417):255-8.	
	C135	KINOSHITA T et al., CD20-negative relapse in B-cell lymphoma after treatment with Rituximab. <i>J Clin Oncol.</i> 1998 Dec;16(12):3916.	
	C136	KOZBOR D et al., A human hybrid myeloma for production of human monoclonal antibodies. <i>J Immunol.</i> 1984 Dec;133(6):3001-5.	

11-29-04

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

FILING DATE: June 22, 2001

APPLICANT: Weiner et al.

GROUP ART UNIT: 1645

EXAMINER: unknown

Sheet 2 of 2

C138 LANGER R, New methods of drug delivery. *Science*. 1990 Sep 28;249(4976):1527-33.

C139 LI X et al., Detection of apoptosis and DNA replication by differential labeling of DNA strand breaks with fluorochromes of different color. *Exp Cell Res*. 1996 Jan 10;222(1):28-37.

C140 LINK BK et al., Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms. *Int J Cancer*. 1998 Jul 17;77(2):251-6.

C141 LINK BK et al., Production and characterization of a bispecific IgG capable of inducing T-cell-mediated lysis of malignant B cells. *Blood*. 1993 Jun 15;81(12):3343-9.

C142 MALONEY DG, Preclinical and phase I and II trials of rituximab. *Semin Oncol*. 1999 Oct;26(5 Suppl 14):74-8.

C143 MARTIN-OROZCO E et al., Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences. *Int Immunol*. 1999 Jul;11(7):1111-8.

C144 MAYUMI M et al., Negative signaling in B cells by surface immunoglobulins. *J Allergy Clin Immunol*. 1996 Dec;98(6 Pt 2):S238-47.

C145 McLAUGHLIN P et al., Clinical status and optimal use of rituximab for B-cell lymphomas. *Oncology (Huntingt)*. 1998 Dec;12(12):1763-9.

C146 McLAUGHLIN P et al., Rituximab in indolent lymphoma: the single-agent pivotal trial. *Semin Oncol*. 1999 Oct;26(5 Suppl 14):79-87.

C147 SCHULTZE JL et al., T cell mediated immunotherapy for B cell lymphoma. *J Mol Med*. 1999 Mar;77(3):322-31.

C148 WAGNER H, Bacterial CpG DNA activates immune cells to signal infectious danger. *Adv Immunol*. 1999;73:329-68.

C149 WAGNER RW et al., Potent and selective inhibition of gene expression by an antisense heptanucleotide. *Nat Biotechnol*. 1996 Jul;14(7):840-4.

C150 WAHL RL et al., Improved radioimaging and tumor localization with monoclonal F(ab')<sub>2</sub>. *J Nucl Med*. 1983 Apr;24(4):316-25.

C151 WISEMAN GA et al., Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody. *Clin Cancer Res*. 1999 Oct;5(10 Suppl):3281s-3286s.

C152 WITZIG TE et al., Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. *J Clin Oncol*. 1999 Dec;17(12):3793-803.

C153 WOOLDRIDGE JE et al., Select unmethylated CpG oligodeoxynucleotides improve antibody-dependent cellular cytotoxicity in vitro and in vivo. ABSTRACT #3253. *Proc Am Assn Cancer Res* 1996 Mar;37:477.

WOOLDRIDGE JE et al., Select unmethylated CpG oligodeoxynucleotides improve antibody dependent cellular cytotoxicity in vitro of both murine and human B cell lymphomas. ABSTRACT #2877. *Blood* 1995 Dec;86:722A.

EXAMINER

DATE CONSIDERED

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 09/888,326	ATTY. DOCKET NO.: C1039/7052
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: June 22, 2001	
		APPLICANT: Weiner et al.	
		GROUP ART UNIT: 1645	EXAMINER: unknown
Sheet	1	of	1



#### U.S. PATENT DOCUMENTS


Examiner's Initials#	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	A39	6,207,646	B1	Krieg et al.	03-27-2001

#### FOREIGN PATENT DOCUMENTS

Examiner's Initials#	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			

#### OTHER ART — NON PATENT LITERATURE DOCUMENTS


Examiner's Initials#	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C154	BAUER M et al., DNA activates human immune cells through a CpG sequence-dependent manner. <i>Immunology</i> . 1999 Aug;97(4):699-705.	
	C155	HARTMANN G et al., CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. <i>Proc Natl Acad Sci U S A</i> . 1999 Aug 3;96(16):9305-10.	
	C156	MACFARLANE DE et al., Immunostimulatory CpG-oligodeoxynucleotides induce a factor that inhibits macrophage adhesion. <i>J Lab Clin Med</i> . 1999 Nov;134(5):501-9.	
	C157	SUN S et al, Type I interferon-mediated stimulation of T cells by CpG DNA. <i>J Exp Med</i> . 1998 Dec 21;188(12):2335-42.	

EXAMINER 	DATE CONSIDERED 11-24-04
--	-----------------------------


#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).


[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]


FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 09/888,326	ATTY. DOCKET NO.: C1039.70052US00
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> 		FILING DATE: June 22, 2001	CONFIRMATION NO.: 7237
		APPLICANT: Weiner et al.	
		GROUP ART UNIT: 1635	EXAMINER: Jon E. Angel
Sheet	1	of	2

### U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	A40	2002/0091097	A1	Bratzler et al.	07-11-2002
	A41	2002/0164341	A1	Davis et al.	11-07-2002
	A42	2003/0050263	A1	Krieg et al.	03-13-2003
	A43	2003/0050268	A1	Krieg et al.	03-13-2003
	A44	2003/0091599	A1	Davis et al.	05-15-2003
	A45	2003/0055014	A1	Bratzler	03-20-2003
	A46	2003/0100527	A1	Krieg et al.	05-29-2003
	A47	2003/0104523	A1	Lipford et al.	06-05-2003
	A48	2003/0139364	A1	Krieg et al.	07-24-2003
	A49	2003/0148976	A1	Krieg et al.	08-07-2003
	A50	2003/0148316	A1	Lipford et al.	08-07-2003
	A51	2003/0166001	A1	Lipford	09-04-2003
	A52	2003/0181406	A1	Schetter et al.	09-25-2003
	A53	2003/0191079	A1	Krieg et al.	10-09-2003
	A54	2003/0232074	A1	Lipford et al.	12-18-2003

### FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
	B34	WO	02/069369	A2		09-06-2002	

EXAMINER 	DATE CONSIDERED 11-24-04
--	-----------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_, filed \_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]